Get started
AstraZeneca PLCAstraZeneca PLCAstraZeneca PLC

AstraZeneca PLC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

AZN chart


Full chart

Key facts today

AstraZeneca reported Q3 sales of $13.57 billion, an 18% year-over-year rise, or 21% at constant currency, exceeding the estimate of $13.09 billion.
AstraZeneca CEO Pascal Soriot expressed confidence in the FDA's role in medical innovation, emphasizing its importance amid concerns about potential changes under Robert F. Kennedy Jr.'s influence.
AstraZeneca's stock price declined by 1.41% during pre-market hours, reflecting a broader downturn in health stocks.
Analyze the impactAnalyze the impact

AZN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪202.08 B‬ USD
Dividend yield (indicated)
2.24%
Price to earnings Ratio (TTM)
31.26
Basic EPS (TTM)
2.10 USD
Net income (FY)
‪5.96 B‬ USD
Revenue (FY)
‪45.81 B‬ USD
Shares float
‪3.10 B‬
Beta (1Y)
0.02

About ASTRAZENECA PLC ORD USD0.25


Sector
Health Technology
CEO
Pascal Soriot
Headquarters
Cambridge
Website
astrazeneca.co.uk
Founded
1992
FIGI
BBG000BZ0DK8
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

AZN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

AZN highest yielding bonds


US46353AM0
ASTRAZENECA PLC 15/45
Yield to maturity
5.39%
Maturity date
Nov 16, 2045
US46353AU2
ASTRAZENECA 18/48
Yield to maturity
5.35%
Maturity date
Aug 17, 2048
AZN.GE
AstraZeneca PLC 6.45% 15-SEP-2037
Yield to maturity
5.26%
Maturity date
Sep 15, 2037
AZN3901525
AstraZeneca PLC 4.0% 18-SEP-2042
Yield to maturity
5.24%
Maturity date
Sep 18, 2042
A
US4636NAN3
ASTRAZEN.FI. 24/34
Yield to maturity
5.13%
Maturity date
Feb 26, 2034
US46353AZ1
ASTRAZENECA 21/51
Yield to maturity
5.05%
Maturity date
May 28, 2051
US46353AX6
ASTRAZENECA 20/50
Yield to maturity
4.93%
Maturity date
Aug 6, 2050
A
AZN5549116
AstraZeneca Finance LLC 4.875% 03-MAR-2033
Yield to maturity
4.92%
Maturity date
Mar 3, 2033
A
US4636NAM5
ASTRAZEN.FI. 24/31
Yield to maturity
4.89%
Maturity date
Feb 26, 2031
A
US4636NAL7
ASTRAZEN.FI. 24/29
Yield to maturity
4.83%
Maturity date
Feb 26, 2029
A
AZN5549115
AstraZeneca Finance LLC 4.9% 03-MAR-2030
Yield to maturity
4.78%
Maturity date
Mar 3, 2030

Explore more bonds 

Sparks


Curated watchlists where AZN is featured.

See all sparks